Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
NMS
May 15, 2023

Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting 

NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of action and potential for First in Class/Best in Class  

Nerviano, 15 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that a poster, describing the currently enrolling phase II part of the trial MPSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.

Title: “Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy”

Session Category: Trials in Progress (TIP); Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Abstract Number: TPS4185

Date and Time: Monday, June 5, 2023,      8:00 AM-11:00 AM (CDT)

link: 20230515 MPS1 2023 ASCO poster_PressRelease

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO